Special Issue "Ways to Eliminate Viral Hepatitis as a Global Health Threat"

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".

Deadline for manuscript submissions: 31 December 2021.

Special Issue Editor

Prof. Dr. Robert Flisiak
E-Mail Website
Guest Editor
Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland
Interests: infectious diseases; viral hepatitis; liver; COVID-19

Special Issue Information

Dear Colleagues,

Hepatitis B (HBV) and C (HCV) have been recognized by the World Health Organization (WHO) as one of the major public health problems worldwide. Hepatotropic viruses are currently estimated to be responsible for the deaths of more than one million people each year, making them comparable in mortality to human immunodeficiency virus (HIV) infections, tuberculosis, and malaria. According to recent epidemiological reports, there are 71 million people living with HCV worldwide. The introduction of highly effective and safe direct-acting antivirals (DAAs) has radically changed the landscape and outlook for HCV treatment. In addition, this revolution on an unprecedented scale in the history of medicine has stimulated epidemiological research and encouraged research teams to create simulations and predictions. In 2016, WHO initiated an ambitious plan to eliminate viral hepatitis as a public health threat by 2030. Unfortunately, the implementation of this ambitious plan has been disrupted by the COVID-19 pandemic, resulting in a reduction in the number of screening tests performed and the number of patients treated for viral hepatitis. This special edition of Viruses aims to provide updated information on efforts and the chances of eliminating viral hepatitis as a global health threat.

Prof. Dr. Robert Flisiak
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • HBV
  • HCV
  • viral hepatitis
  • therapy
  • screening
  • elimination

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


One-Year Outcomes after Ledipasvir/Sofosbuvir Treatment of Chronic Hepatitis C in Teenagers with and without Significant Liver Fibrosis—A Case Series Report
Viruses 2021, 13(8), 1518; https://0-doi-org.brum.beds.ac.uk/10.3390/v13081518 - 31 Jul 2021
Viewed by 756
One-year outcomes after therapy with ledipasvir/sofosbuvir (LDV/SOF) in children with chronic hepatitis C (CHC) presenting with and without significant liver fibrosis were analyzed. We included patients aged 12–17 years treated with LDV/SOF, presenting with significant fibrosis (F ≥ 2 on the METAVIR scale) [...] Read more.
One-year outcomes after therapy with ledipasvir/sofosbuvir (LDV/SOF) in children with chronic hepatitis C (CHC) presenting with and without significant liver fibrosis were analyzed. We included patients aged 12–17 years treated with LDV/SOF, presenting with significant fibrosis (F ≥ 2 on the METAVIR scale) in transient elastography (TE) at the baseline and we compared the outcomes with that of patients without fibrosis. Patients were followed every 4 weeks during the treatment, at the end of the therapy, at week 12 posttreatment, and one year after the end of treatment. Liver fibrosis was established using noninvasive methods: TE, aspartate transaminase-to-platelet ratio index (APRI), and Fibrosis-4 index (FIB-4). There were four patients with significant fibrosis at baseline: one with a fibrosis score of F2 on the METAVIR scale, and three with cirrhosis (F4) at baseline. One year after the end of treatment, the hepatitis C viral load was undetectable in three of them. One patient was lost to follow-up after week 4. In two out of the four patients, a significant improvement and regression of liver fibrosis was observed (from stage F4 and F2 to F0-F1 on the METAVIR scale). In one patient, the liver stiffness measurement median increased 12 weeks after the end of the treatment and then decreased, but still correlated with stage F4. An improvement in the APRI was observed in all patients. In four patients without fibrosis, the treatment was effective and no progression of fibrosis was observed. A one-year observation of teenagers with CHC and significant fibrosis treated with LDV/SOF revealed that regression of liver fibrosis is possible, but not certain. Further observations in larger groups of patients are necessary to find predictors of liver fibrosis regression. Full article
(This article belongs to the Special Issue Ways to Eliminate Viral Hepatitis as a Global Health Threat)
Show Figures

Figure 1

Back to TopTop